Clinical Trials

Title   A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Description   The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo.
IRB Number   18-012
Treatment   Oncology - Breast Cancer
Status   Active
Start Date   01/10/2018
Principal Name   Lynn Dyess MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us